Immune–hemostatic crosstalk in diabetic retinopathy: amplifiers, secondary signatures, and evidence boundaries

Diabetic retinopathy (DR) develops within a neurovascular environment in which inflammatory and hemostatic processes intersect, but the abnormalities reported across these systems do not carry equal causal weight. This Review evaluates where immune–hemostatic crosstalk contributes to retinal injury and where it more likely reflects barrier failure, systemic diabetes, or advanced disease. We assess temporal precedence, retinal localization, experimental directionality, interventional support, replication, and agreement with human observations. Among the selected mechanisms reviewed here, endothelial activation and adhesion-dependent leukostasis have the strongest experimental support for selected early retinal vascular endpoints, although their contribution to persistent human retinal nonperfusion remains unresolved. Nonperfusion, hypoxic stress, vascular endothelial growth factor (VEGF) signaling, blood–retinal barrier dysfunction, and neuroglial injury interact rather than follow a fixed sequence. Fibrinogen/fibrin is most convincingly placed downstream of barrier failure, where it can exert secondary inflammatory effects. Neutrophil extracellular traps have context-dependent actions across retinal pathological states, whereas most platelet findings remain secondary/systemic signatures. Human VWF–ADAMTS13 evidence is predominantly associative, whereas ADAMTS13 supplementation and suppression have both shown protective effects on selected retinal endpoints in non-equivalent experimental models. Thrombin–PAR1 signaling is an emerging mechanism with incomplete human validation. This evidence-stratified synthesis therefore identifies experimentally supported amplifiers without recasting DR as a unified immunothrombotic disease.

Authors

Institutions

Publication Details

Journal
Frontiers in Medicine
Published
2026-11-13
DOI
https://doi.org/10.3389/fmed.2026.2012279
Primary Topic
Retinal Diseases and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Immune–hemostatic crosstalk in diabetic retinopathy: amplifiers, secondary signatures, and evidence boundaries

Xiaorong Li, Fengyan Zhang, Qing Liu
1 links
Frontiers in Medicine
Retinal Diseases and Treatments
article

Immune–hemostatic crosstalk in diabetic retinopathy: amplifiers, secondary signatures, and evidence boundaries

Xiaorong Li, Fengyan Zhang, Qing Liu
article en

Abstract

Diabetic retinopathy (DR) develops within a neurovascular environment in which inflammatory and hemostatic processes intersect, but the abnormalities reported across these systems do not carry equal causal weight. This Review evaluates where immune–hemostatic crosstalk contributes to retinal injury and where it more likely reflects barrier failure, systemic diabetes, or advanced disease. We assess temporal precedence, retinal localization, experimental directionality, interventional support, replication, and agreement with human observations. Among the selected mechanisms reviewed here, endothelial activation and adhesion-dependent leukostasis have the strongest experimental support for selected early retinal vascular endpoints, although their contribution to persistent human retinal nonperfusion remains unresolved. Nonperfusion, hypoxic stress, vascular endothelial growth factor (VEGF) signaling, blood–retinal barrier dysfunction, and neuroglial injury interact rather than follow a fixed sequence. Fibrinogen/fibrin is most convincingly placed downstream of barrier failure, where it can exert secondary inflammatory effects. Neutrophil extracellular traps have context-dependent actions across retinal pathological states, whereas most platelet findings remain secondary/systemic signatures. Human VWF–ADAMTS13 evidence is predominantly associative, whereas ADAMTS13 supplementation and suppression have both shown protective effects on selected retinal endpoints in non-equivalent experimental models. Thrombin–PAR1 signaling is an emerging mechanism with incomplete human validation. This evidence-stratified synthesis therefore identifies experimentally supported amplifiers without recasting DR as a unified immunothrombotic disease.

Frontiers in MedicineVol. 13
Tianjin Medical University Eye Hospital (CN), Tianjin Medical University (CN)
Good health and well-being
Retinal Diseases and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon